<DOC>
	<DOCNO>NCT00237133</DOCNO>
	<brief_summary>Open-label Phase IV trial Letrozole 2,5mg po/day 120 day prior surgery patient locally advance breast postmenopausal woman express hormonal receptor ( ER PR )</brief_summary>
	<brief_title>Treatment Locally Advanced Breast Cancer With Letrozole Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>1 . Postmenopausal woman 2 . Primary locally invasive breast cancer 3 . Histological confirm core needle biopsy , whose tumor estrogen ( ER ) / progesterone ( PgR ) positive , define core biopsy immunohistochemistry &gt; 10 % positive malignant epithelial cell . 4 . Post menopausal status 5 . Tumor measurable clinical examination , mammography ultrasound 1 . Prior treatment letrozole tamoxifen . 2 . Patients bilateral breast tumor 3 . Patients eligible breast conserving surgery 4 . Evidence inflammatory breast cancer distant metastasis . 5 . Other concurrent malignant disease 6 . Concomitant anticancer treatment chemotherapy Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Breast cancer ,</keyword>
	<keyword>Letrozole ,</keyword>
	<keyword>Hormonal receptor</keyword>
</DOC>